2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T7748,

Summary Table

Category	Details
Risk Factors	Sporadic pituitary somatotroph adenoma (most cases). Genetic syndromes: MEN1, Carney complex, McCune-Albright syndrome, familial isolated pituitary adenoma (AIP gene mutation). Acromegaly typically presents at age 30 to 50; gigantism presents pre-puberty or in adolescence (before epiphyseal closure)
Etiology	Growth hormone (GH) hypersecretion. >95% from a benign GH-secreting pituitary adenoma. Rare: ectopic GHRH from bronchial/pancreatic carcinoid; ectopic GH secretion (very rare)
Patient Presentation	Gigantism: rapid linear growth, abnormally tall stature in a child or adolescent. Acromegaly: rings no longer fit, shoes outgrown, hat size increased, coarsening facial features, headache, joint pain, excessive sweating, snoring/sleep apnea, fatigue, decreased libido, vision changes, amenorrhea/galactorrhea (if prolactin co-secretion)
Classic Physical Exam	Enlarged hands and feet (spade-like), coarse facial features, frontal bossing, prognathism, increased interdental spacing, macroglossia, deep voice, oily/thickened skin, skin tags (acrochordons), hyperhidrosis, carpal tunnel signs (Tinel/Phalen), bitemporal hemianopia (if macroadenoma), hypertension, signs of cardiomyopathy. In gigantism: tall stature plus the acromegalic features above
Key Diagnostic Results	Elevated serum IGF-1 (age- and sex-adjusted), failure of GH suppression below 1 ng/mL (or <0.4 ng/mL ultrasensitive assay) after a 75 g oral glucose load, pituitary adenoma on MRI with contrast
Management	Transsphenoidal adenomectomy (first-line). Medical therapy: somatostatin receptor ligands (octreotide LAR, lanreotide depot, pasireotide), dopamine agonist (cabergoline), GH receptor antagonist (pegvisomant). Stereotactic or fractionated radiotherapy as adjunct. Treat comorbidities (diabetes, hypertension, sleep apnea, cardiomyopathy)
Keywords	"Rings no longer fit," "shoes don't fit anymore," "hat size increased," "sweaty handshake," coarse features, frontal bossing, prognathism, macroglossia, spade-like hands, skin tags, bitemporal hemianopia, "tunica" (carpal tunnel), failure of GH suppression after oral glucose, elevated IGF-1, pituitary macroadenoma

1. Pathophysiology

Both gigantism and acromegaly are driven by chronic, autonomous oversecretion of growth hormone (GH) from a benign somatotroph adenoma in the anterior pituitary. The adenoma loses normal feedback regulation, so GH continues to be released despite negative feedback signals from IGF-1, somatostatin, and hyperglycemia. GH then acts on the liver to stimulate IGF-1 production, and IGF-1 is the primary mediator of most peripheral anabolic and growth effects. This is why IGF-1, not GH, is the most reliable circulating biomarker: GH is pulsatile and varies widely throughout the day, while IGF-1 reflects integrated 24-hour GH activity.

The clinical phenotype depends on whether the epiphyseal growth plates are still open. In children and adolescents, GH excess accelerates linear bone growth at the epiphyses, producing gigantism with abnormally tall stature. Once the epiphyses fuse at puberty, longitudinal growth stops, but periosteal and appositional bone growth, cartilage proliferation, and soft tissue overgrowth continue. This produces the acral and facial overgrowth that defines acromegaly: enlarged hands and feet, frontal bossing, prognathism, interdental spacing, macroglossia, and thickened skin.

GH directly antagonizes insulin action at the post-receptor level, producing insulin resistance, glucose intolerance, and frank diabetes mellitus in roughly a third of patients. This is a high-yield association. GH and IGF-1 also promote sodium retention and produce a hyperdynamic circulation, leading to hypertension, biventricular hypertrophy, diastolic dysfunction, and eventually a dilated cardiomyopathy, which is the leading cause of death in untreated disease.

Tumor mass effects are equally testable. A macroadenoma (>=10 mm) growing superiorly compresses the optic chiasm and produces bitemporal hemianopia. Lateral extension into the cavernous sinus can affect cranial nerves III, IV, V1, V2, and VI. Compression of normal pituitary tissue causes hypopituitarism, with secondary hypogonadism appearing earliest (amenorrhea, decreased libido, erectile dysfunction). Stalk compression can also disinhibit prolactin, producing mild hyperprolactinemia (the stalk effect), which must be distinguished from a true co-secreting adenoma.

Soft tissue overgrowth in the upper airway produces obstructive sleep apnea, and median nerve compression at the wrist produces carpal tunnel syndrome, both of which are commonly featured in vignettes. Increased epithelial proliferation also raises the risk of colonic polyps and colorectal cancer, which is why colonoscopy screening is part of routine workup.

2. Classification and Clinical Manifestations

Classification Axis	Categories	Key Features
By timing of GH excess	Gigantism	Onset before epiphyseal fusion; abnormally tall stature, rapid linear growth, plus eventual acromegalic features
By timing of GH excess	Acromegaly	Onset after epiphyseal fusion; acral and soft tissue overgrowth without increased height
By tumor size	Microadenoma (<10 mm)	Higher surgical cure rate; usually no mass effect
By tumor size	Macroadenoma (>=10 mm)	Headache, bitemporal hemianopia, hypopituitarism, cavernous sinus invasion possible
By secretory profile	Pure GH-secreting	Densely or sparsely granulated somatotroph adenoma
By secretory profile	Mixed GH/prolactin co-secreting (mammosomatotroph)	Galactorrhea, amenorrhea, infertility plus acromegalic features; responds well to dopamine agonists
By etiology	Sporadic somatotroph adenoma	Most common (>95%)
	Genetic/syndromic	MEN1 (parathyroid + pancreatic + pituitary tumors), Carney complex (myxomas, spotty pigmentation, endocrine tumors), McCune-Albright (precocious puberty, polyostotic fibrous dysplasia, cafe-au-lait), familial isolated pituitary adenoma (AIP mutation, often young onset and aggressive)
	Ectopic GHRH/GH	Bronchial or pancreatic neuroendocrine tumor producing GHRH; presents identically but pituitary may show hyperplasia rather than adenoma on MRI

Systemic manifestations are distributed across organ systems:

System	Manifestations
Skeletal/joint	Frontal bossing, prognathism, interdental spacing, malocclusion, enlarged hands and feet, arthropathy of large joints (hips, knees), kyphosis
Soft tissue/skin	Coarse features, doughy/oily skin, skin tags, hyperhidrosis, deep nasolabial folds, macroglossia, deepened voice
Cardiovascular	Hypertension, left ventricular hypertrophy, diastolic dysfunction, dilated cardiomyopathy, arrhythmias; leading cause of mortality
Respiratory	Obstructive sleep apnea (often severe), upper airway soft tissue overgrowth
Metabolic	Insulin resistance, impaired glucose tolerance, type 2 diabetes, hypertriglyceridemia
Neurologic	Headache, carpal tunnel syndrome, peripheral neuropathy, bitemporal hemianopia (if macroadenoma)
Endocrine	Secondary hypogonadism (most common), hypothyroidism, secondary adrenal insufficiency (with macroadenomas)
Oncologic	Increased risk of colonic adenomas and colorectal carcinoma, possibly thyroid nodules

3. Diagnostic Workup

Step	Test	Purpose
1. Best Initial (Screening)	Serum IGF-1 (age- and sex-matched reference)	Reflects integrated GH activity; pulsatility of GH makes random GH unreliable
2. Confirmatory (Gold Standard)	Oral glucose tolerance test with serial GH measurement (75 g glucose; GH at 0, 30, 60, 90, 120 min)	Failure to suppress GH below 1 ng/mL (or <0.4 ng/mL with ultrasensitive assay) confirms diagnosis
3. Localization	Pituitary MRI with gadolinium	Identify adenoma; classify as micro- vs macroadenoma; assess optic chiasm and cavernous sinus
4. If MRI negative	Serum GHRH; chest/abdominal imaging	Look for ectopic GHRH source (bronchial/pancreatic neuroendocrine tumor)
5. Visual assessment	Formal visual field testing	If macroadenoma abuts/compresses optic chiasm
6. Anterior pituitary panel	Prolactin, TSH, free T4, ACTH, cortisol, LH, FSH, testosterone/estradiol	Screen for hypopituitarism and prolactin co-secretion
7. Comorbidity screening	HbA1c, fasting glucose, lipids, ECG, echocardiogram, polysomnography, colonoscopy	Identify treatable end-organ damage
8. Genetic context	Calcium, PTH (MEN1 screen) if young patient or family history	Identify syndromic disease

The workup follows a logical sequence: biochemical confirmation comes before imaging. Ordering an MRI first is a common error, because incidental pituitary microadenomas (incidentalomas) are found in roughly 10% of normal adults, and an MRI finding without biochemical confirmation can mislead.

The best initial test is serum IGF-1. GH itself is secreted in pulses and has a short half-life, so a random GH level is uninterpretable. IGF-1 has a long half-life and reflects integrated GH secretion over the preceding 24 hours. An elevated IGF-1, adjusted for age and sex, is the trigger for further testing. Note that pregnancy, late adolescence, and severe systemic illness can confound IGF-1 interpretation.

The most accurate confirmatory test is the oral glucose tolerance test. In healthy individuals, a glucose load suppresses GH below 1 ng/mL (or below 0.4 ng/mL with ultrasensitive assays). In acromegaly, the autonomous adenoma fails to suppress, and GH remains elevated or paradoxically rises. This test combines high sensitivity with the ability to demonstrate loss of normal feedback regulation, which is the physiologic essence of the disease.

Once the biochemistry is confirmed, MRI of the pituitary with contrast localizes the adenoma. Microadenomas (<10 mm) are usually fully resectable; macroadenomas (>=10 mm) raise concern for chiasmal compression and cavernous sinus invasion. If the MRI is unrevealing despite clear biochemistry, the next step is to measure serum GHRH and image the chest and abdomen to look for an ectopic GHRH-secreting neuroendocrine tumor.

Comorbidity assessment is part of the initial workup, not an afterthought. Echocardiography, sleep study, fasting glucose/HbA1c, lipid panel, and colonoscopy are routinely ordered because cardiovascular disease drives mortality and colon cancer risk is elevated.

4. Management and Treatment

Modality	Agent/Approach	Dose and Frequency	Role
Surgery	Transsphenoidal adenomectomy	One-time procedure	First-line for nearly all patients; potentially curative
Somatostatin receptor ligand	Octreotide LAR	20 to 30 mg intramuscular every 4 weeks	First-line medical therapy after incomplete surgical cure
	Lanreotide depot	90 to 120 mg deep subcutaneous every 4 weeks	Equivalent to octreotide LAR
	Pasireotide LAR	20 to 60 mg intramuscular every 4 weeks	Second-line; more potent but higher rate of hyperglycemia
Dopamine agonist	Cabergoline	0.5 to 3.5 mg orally per week	Mild disease, modest IGF-1 elevation, or prolactin co-secretion
GH receptor antagonist	Pegvisomant	10 to 30 mg subcutaneous daily	For patients refractory or intolerant to somatostatin ligands; normalizes IGF-1 but does not shrink tumor
Radiotherapy	Stereotactic radiosurgery or fractionated external beam	One session (radiosurgery) or multi-week course	Adjunct when surgery and medical therapy fail; effect takes years; risk of hypopituitarism
Comorbidity management	Antihypertensives, glucose-lowering agents, CPAP, statins, colonoscopy surveillance	Per relevant guidelines	Mortality reduction

Transsphenoidal adenomectomy is the first-line treatment for nearly every patient, regardless of tumor size, provided the patient is a surgical candidate. Cure rates approach 85% to 90% for microadenomas and 40% to 50% for macroadenomas, with outcomes heavily dependent on the experience of the pituitary surgeon. Cure is defined biochemically as normalization of IGF-1 and a GH nadir below 1 ng/mL on oral glucose tolerance testing (or below 0.4 ng/mL with ultrasensitive assays).

When surgery does not achieve biochemical remission, or when the tumor is unresectable or invasive, medical therapy is the next step. The first-line medical agents are long-acting somatostatin receptor ligands, octreotide LAR or lanreotide depot. These bind somatostatin receptor subtype 2 on the adenoma, suppressing GH release and producing modest tumor shrinkage in roughly half of patients. Common adverse effects include gallstones, diarrhea, nausea, and worsening glucose tolerance.

Pasireotide LAR is a second-generation somatostatin ligand that binds multiple receptor subtypes and is more potent but produces hyperglycemia in a substantial portion of patients, sometimes precipitating diabetes. Cabergoline, a dopamine D2 agonist, is useful when IGF-1 elevation is mild or when the tumor co-secretes prolactin (mammosomatotroph adenoma); response is best when prolactin is elevated. Pegvisomant is a GH receptor antagonist that blocks peripheral GH action and reliably normalizes IGF-1 in over 90% of patients, but it does not suppress GH release or shrink the tumor, so MRI surveillance is required.

Radiotherapy, either stereotactic radiosurgery (Gamma Knife) or fractionated external beam, is an adjunct for residual or recurrent disease. The biochemical response takes years to develop, and the principal long-term risk is hypopituitarism, which develops in roughly half of patients within ten years.

The "Next Best Step" logic is testable in stepwise form. If a vignette describes coarsening features and enlarged hands, the next best step is to order IGF-1, not an MRI. If IGF-1 is elevated, the next best step is the oral glucose tolerance test, not imaging. If both confirm the diagnosis, the next best step is MRI of the pituitary. Once an adenoma is localized and the patient is a surgical candidate, the next best step is referral for transsphenoidal surgery.

Long-term management involves lifelong biochemical surveillance (annual IGF-1, periodic OGTT), pituitary MRI follow-up, and active treatment of comorbidities. Tight control of blood pressure, glucose, and sleep apnea normalizes the previously elevated cardiovascular mortality. Colonoscopy screening is performed at diagnosis and at intervals thereafter.

Contraindications and cautions include cabergoline in patients with significant cardiac valvulopathy at high cumulative doses (a class effect of ergot dopamine agonists), pasireotide in patients with poorly controlled diabetes, and pegvisomant monotherapy in patients with rapidly growing tumors (since it does not address the adenoma itself). In pregnancy, somatostatin ligands and pegvisomant are generally withheld unless required, and most patients can be managed conservatively because pregnancy itself often improves disease control.

5. Differential Diagnosis and Distractors

Differential Diagnosis	Why It Looks Similar	Key Discriminator
Familial/constitutional tall stature	Adolescent presents with tall stature; often the first concern when gigantism is suspected	Linear growth tracks parental heights, no soft tissue overgrowth, normal IGF-1 and normal GH suppression on OGTT
Marfan syndrome	Tall stature, long extremities, may have facial findings	Arachnodactyly, ectopia lentis, aortic root dilation, joint hypermobility, positive family history; IGF-1 normal
Pseudoacromegaly (insulin-mediated)	Acral enlargement and coarse features in obese, severely insulin-resistant patient	Normal IGF-1, normal GH suppression on OGTT; driven by hyperinsulinemia acting on IGF-1 receptor
Primary hypothyroidism	Coarse facial features, doughy skin, fatigue, sleep disturbance, carpal tunnel	Bradycardia, weight gain, cold intolerance, delayed reflexes, elevated TSH and low free T4; no acral overgrowth, normal IGF-1
Cushing syndrome	Facial fullness, hypertension, glucose intolerance, sleep disturbance, hirsutism in women	Central obesity with thin extremities, purple striae, proximal myopathy, supraclavicular fat pad; elevated cortisol and failure of dexamethasone suppression rather than failed GH suppression
Prolactinoma with stalk effect	Pituitary macroadenoma, headache, visual field defect, mild hyperprolactinemia, hypogonadism	Prolactin usually >200 ng/mL in true prolactinoma; absence of acral and facial overgrowth; normal IGF-1
McCune-Albright syndrome (in a child)	Cafe-au-lait macules, polyostotic fibrous dysplasia, precocious puberty, can include GH excess	Cafe-au-lait with irregular borders ("coast of Maine"), bone deformities, peripheral precocious puberty; may overlap when GH excess co-exists
Multiple endocrine neoplasia type 1 (MEN1)	Pituitary adenoma can be GH-secreting	Co-existing primary hyperparathyroidism (hypercalcemia) and pancreatic neuroendocrine tumor (gastrinoma, insulinoma); family history; menin gene mutation
Paget disease of bone	Frontal bossing, enlarged skull, headache, deafness	Markedly elevated alkaline phosphatase with normal calcium, lytic and sclerotic bony lesions on imaging, no acral soft tissue change, normal IGF-1
Ectopic GHRH secretion	Identical clinical and biochemical picture to acromegaly	MRI shows pituitary hyperplasia rather than discrete adenoma; elevated serum GHRH; chest or abdominal neuroendocrine tumor

6. Traps and High-Yield Pearls

The single most common error is ordering a random GH level or going straight to pituitary MRI when acromegaly is suspected. GH is pulsatile, so a random value is uninterpretable; pituitary incidentalomas are common, so an MRI without biochemical confirmation can mislead. The correct sequence is IGF-1 first, then oral glucose tolerance test for confirmation, then MRI for localization.

The second high-yield trap is forgetting that acromegaly kills through the heart, not the head. The leading cause of death is cardiovascular disease (cardiomyopathy, hypertension, arrhythmia), not the pituitary tumor itself. Vignettes describing a long-standing acromegalic patient who develops dyspnea on exertion are testing recognition of acromegalic cardiomyopathy with diastolic dysfunction. Closely linked is obstructive sleep apnea, which is present in well over half of patients and contributes to both daytime fatigue and cardiac morbidity.

A third trap is the insidious onset and diagnostic delay. The average time from symptom onset to diagnosis is seven to ten years, and the patient's chief complaint is often not "I have acromegaly" but rather a complication: new-onset diabetes, hypertension, carpal tunnel, sleep apnea, joint pain, headache, or a change in ring or shoe size. The vignette teaches you to recognize the constellation of soft tissue overgrowth plus a metabolic complication as the pattern, not a single feature.

A fourth pearl concerns prolactin co-secretion and the stalk effect. Mildly elevated prolactin in a patient with a pituitary macroadenoma can be due to either a true co-secreting tumor or stalk compression by a non-functioning macroadenoma. The distinction matters because mammosomatotroph adenomas respond well to cabergoline, while pure somatotroph adenomas usually require somatostatin ligands.

A fifth pearl is the colorectal cancer association. Patients with acromegaly have an increased risk of colon polyps and colorectal carcinoma, so colonoscopy is part of the initial workup and is repeated periodically. Vignettes featuring an acromegalic patient with iron deficiency anemia or a positive fecal occult blood test are testing this association.

The sixth and most testable distinction is between gigantism and acromegaly, which comes down to a single anatomic fact: the state of the epiphyseal growth plates. GH excess before epiphyseal closure produces longitudinal bone growth and tall stature; GH excess after closure produces only soft tissue and appositional bone changes without increased height. A patient who develops both (rare) had GH excess that began in childhood and continued into adulthood.

Finally, recognize the next-best-step logic that examiners reward: confirm biochemically before imaging, treat surgically before medically when feasible, normalize IGF-1 as the goal of therapy, and screen aggressively for the systemic complications that determine long-term mortality. The competency being tested is recognizing a slow, multi-system clinical pattern, sequencing biochemical and imaging studies correctly, and matching treatment modality to tumor characteristics and surgical outcome.

1e:["$","$L2d",null,{"article":{"id":"9e19aa7d-a657-4f94-9e18-5acb268fc166","title":"Gigantisme & Akromegali","content":"$2e","category":"Endokrin-Metabolik","created_at":"2026-05-04T04:28:23.997614+00:00","status":"published","subcategory":null},"questionCount":6,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestations","num":"02","title":"Classification and Clinical Manifestations"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]